Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature

Alectinib can cause rare, but severe hypersensitivity. The cross-reactivity between different ALK inhibitors is unknown and desensitization is the only reported management. We hereby report the first case of severe delayed hypersensitivity developed in a lung cancer patient treated by alectinib, who...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Lei, Sharma, Janaki, Ravera, Elizabeth, Halmos, Balazs, Cheng, Haiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134951/
https://www.ncbi.nlm.nih.gov/pubmed/30233266
http://dx.doi.org/10.2147/LCTT.S173948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134951/
https://www.ncbi.nlm.nih.gov/pubmed/30233266
http://dx.doi.org/10.2147/LCTT.S173948

Ejemplares similares